|
|
| Line 1: |
Line 1: |
| {{DrugProjectFormSinglePage
| |
| |authorTag={{Steven}}
| |
| <!--Overview-->
| |
| |aOrAn=an
| |
| |drugClass=anthrcycline
| |
| |indicationType=treatment
| |
| |indication=advanced HIV-associated Kaposi's sarcoma
| |
| |hasBlackBoxWarning=Yes
| |
| |adverseReactions=
| |
|
| |
|
| <!--Black Box Warning-->
| |
|
| |
| |blackBoxWarningTitle=<span style="color:#FF0000;">WARNINGS</span>
| |
| |blackBoxWarningBody=
| |
| * Cardiac function should be monitored regularly in patients receiving DaunoXome (daunorubicin citrate liposome injection) because of the potential risk for cardiac toxicity and congestive heart failure. Cardiac monitoring is advised especially in those patients who have received prior anthracyclines or who have pre-existing cardiac disease or who have had prior radiotherapy encompassing the heart.
| |
| * Severe myelosuppression may occur.
| |
| * DaunoXome should be administered only under the supervision of a physician who is experienced in the use of cancer chemotherapeutic agents.
| |
| * Dosage should be reduced in patients with impaired hepatic function.
| |
| * A triad of back pain, flushing, and chest tightness has been reported in 13.8% of the patients (16/116) treated with DaunoXome in the Phase III clinical trial, and in 2.7% of treatment cycles (27/994). This triad generally occurs during the first five minutes of the infusion, subsides with interruption of the infusion, and generally does not recur if the infusion is then resumed at a slower rate.
| |
| <!--Adult Indications and Dosage-->
| |
|
| |
| <!--FDA-Labeled Indications and Dosage (Adult)-->
| |
| |fdaLIADAdult======Condition1=====
| |
|
| |
| * Dosing Information
| |
|
| |
| :* Dosage
| |
|
| |
| =====Condition2=====
| |
|
| |
| * Dosing Information
| |
|
| |
| :* Dosage
| |
|
| |
| =====Condition3=====
| |
|
| |
| * Dosing Information
| |
|
| |
| :* Dosage
| |
|
| |
| =====Condition4=====
| |
|
| |
| * Dosing Information
| |
|
| |
| :* Dosage
| |
|
| |
| <!--Off-Label Use and Dosage (Adult)-->
| |
|
| |
| <!--Guideline-Supported Use (Adult)-->
| |
| |offLabelAdultGuideSupport======Condition1=====
| |
|
| |
| * Developed by:
| |
|
| |
| * Class of Recommendation:
| |
|
| |
| * Strength of Evidence:
| |
|
| |
| * Dosing Information
| |
|
| |
| :* Dosage
| |
|
| |
| =====Condition2=====
| |
|
| |
| There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
| |
|
| |
| <!--Non–Guideline-Supported Use (Adult)-->
| |
| |offLabelAdultNoGuideSupport======Condition1=====
| |
|
| |
| * Dosing Information
| |
|
| |
| :* Dosage
| |
|
| |
| =====Condition2=====
| |
|
| |
| There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
| |
|
| |
| <!--Pediatric Indications and Dosage-->
| |
|
| |
| <!--FDA-Labeled Indications and Dosage (Pediatric)-->
| |
| |fdaLIADPed======Condition1=====
| |
|
| |
| * Dosing Information
| |
|
| |
| :* Dosage
| |
|
| |
| =====Condition2=====
| |
|
| |
| There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
| |
|
| |
| <!--Off-Label Use and Dosage (Pediatric)-->
| |
|
| |
| <!--Guideline-Supported Use (Pediatric)-->
| |
| |offLabelPedGuideSupport======Condition1=====
| |
|
| |
| * Developed by:
| |
|
| |
| * Class of Recommendation:
| |
|
| |
| * Strength of Evidence:
| |
|
| |
| * Dosing Information
| |
|
| |
| :* Dosage
| |
|
| |
| =====Condition2=====
| |
|
| |
| There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
| |
|
| |
| <!--Non–Guideline-Supported Use (Pediatric)-->
| |
| |offLabelPedNoGuideSupport======Condition1=====
| |
|
| |
| * Dosing Information
| |
|
| |
| :* Dosage
| |
|
| |
| =====Condition2=====
| |
|
| |
| There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
| |
|
| |
| <!--Contraindications-->
| |
| |contraindications=* Condition1
| |
|
| |
| <!--Warnings-->
| |
| |warnings=* Description
| |
|
| |
| ====Precautions====
| |
|
| |
| * Description
| |
|
| |
| <!--Adverse Reactions-->
| |
|
| |
| <!--Clinical Trials Experience-->
| |
| |clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
| |
|
| |
| =====Body as a Whole=====
| |
|
| |
|
| |
|
| |
|
| |
| =====Cardiovascular=====
| |
|
| |
|
| |
|
| |
|
| |
| =====Digestive=====
| |
|
| |
|
| |
|
| |
|
| |
| =====Endocrine=====
| |
|
| |
|
| |
|
| |
|
| |
| =====Hematologic and Lymphatic=====
| |
|
| |
|
| |
|
| |
|
| |
| =====Metabolic and Nutritional=====
| |
|
| |
|
| |
|
| |
|
| |
| =====Musculoskeletal=====
| |
|
| |
|
| |
|
| |
|
| |
| =====Neurologic=====
| |
|
| |
|
| |
|
| |
|
| |
| =====Respiratory=====
| |
|
| |
|
| |
|
| |
|
| |
| =====Skin and Hypersensitivy Reactions=====
| |
|
| |
|
| |
|
| |
|
| |
| =====Special Senses=====
| |
|
| |
|
| |
|
| |
|
| |
| =====Urogenital=====
| |
|
| |
|
| |
|
| |
|
| |
| =====Miscellaneous=====
| |
|
| |
|
| |
|
| |
| <!--Postmarketing Experience-->
| |
| |postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
| |
|
| |
| =====Body as a Whole=====
| |
|
| |
|
| |
|
| |
| =====Cardiovascular=====
| |
|
| |
|
| |
|
| |
| =====Digestive=====
| |
|
| |
|
| |
|
| |
| =====Endocrine=====
| |
|
| |
|
| |
|
| |
| =====Hematologic and Lymphatic=====
| |
|
| |
|
| |
|
| |
| =====Metabolic and Nutritional=====
| |
|
| |
|
| |
|
| |
| =====Musculoskeletal=====
| |
|
| |
|
| |
|
| |
| =====Neurologic=====
| |
|
| |
|
| |
|
| |
| =====Respiratory=====
| |
|
| |
|
| |
|
| |
| =====Skin and Hypersensitivy Reactions=====
| |
|
| |
|
| |
|
| |
| =====Special Senses=====
| |
|
| |
|
| |
|
| |
| =====Urogenital=====
| |
|
| |
|
| |
|
| |
| =====Miscellaneous=====
| |
|
| |
|
| |
|
| |
| <!--Drug Interactions-->
| |
| |drugInteractions=* Drug
| |
| :* Description
| |
|
| |
| <!--Use in Specific Populations-->
| |
| |useInPregnancyFDA=* '''Pregnancy Category'''
| |
| |useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
| |
|
| |
| There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
| |
| |useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
| |
| |useInNursing=There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
| |
| |useInPed=There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
| |
| |useInGeri=There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
| |
| |useInGender=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
| |
| |useInRace=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
| |
| |useInRenalImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
| |
| |useInHepaticImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
| |
| |useInReproPotential=There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
| |
| |useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
| |
|
| |
| <!--Administration and Monitoring-->
| |
| |administration=* Oral
| |
|
| |
| * Intravenous
| |
| |monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
| |
|
| |
| * Description
| |
|
| |
| <!--IV Compatibility-->
| |
| |IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
| |
|
| |
| <!--Overdosage-->
| |
| |overdose====Acute Overdose===
| |
|
| |
| ====Signs and Symptoms====
| |
|
| |
| * Description
| |
|
| |
| ====Management====
| |
|
| |
| * Description
| |
|
| |
| ===Chronic Overdose===
| |
|
| |
| There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
| |
|
| |
| <!--Pharmacology-->
| |
|
| |
| <!--Drug box 2-->
| |
| |drugBox=<!--Mechanism of Action-->
| |
| |mechAction=*
| |
|
| |
| <!--Structure-->
| |
| |structure=*
| |
|
| |
| : [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
| |
|
| |
| <!--Pharmacodynamics-->
| |
| |PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
| |
|
| |
| <!--Pharmacokinetics-->
| |
| |PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
| |
|
| |
| <!--Nonclinical Toxicology-->
| |
| |nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
| |
|
| |
| <!--Clinical Studies-->
| |
| |clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
| |
|
| |
| <!--How Supplied-->
| |
| |howSupplied=*
| |
| |packLabel=<!--Patient Counseling Information-->
| |
| |fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
| |
|
| |
| <!--Precautions with Alcohol-->
| |
| |alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
| |
|
| |
| <!--Brand Names-->
| |
| |brandNames=* ®<ref>{{Cite web | title = | url = }}</ref>
| |
|
| |
| <!--Look-Alike Drug Names-->
| |
| |lookAlike=* A® — B®<ref name="www.ismp.org">{{Cite web | last = | first = | title = http://www.ismp.org | url = http://www.ismp.org | publisher = | date = }}</ref>
| |
|
| |
| <!--Drug Shortage Status-->
| |
| |drugShortage=
| |
| }}
| |
| {{PillImage
| |
| |fileName=No image.jpg
| |
| }}
| |
| {{LabelImage
| |
| |fileName={{PAGENAME}}11.png
| |
| }}
| |
| {{LabelImage
| |
| |fileName={{PAGENAME}}11.png
| |
| }}
| |
| <!--Pill Image-->
| |
|
| |
|
| |
|
| |
| <!--Label Display Image-->
| |
|
| |
|
| |
|
| |
|
| |
|
| |
| <!--Category-->
| |
|
| |
| [[Category:Drug]]
| |